checkAd
    Startseite > Aktien > Inhibikase Therapeutics > Nachrichten
    Inhibikase Therapeutics Aktie
    1,7300
     
    USD
    -1,70 %
    -0,0300 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,7400
     
    USD
    200 STK
    Geldkurs 17.05.24
    1,7700
     
    USD
    800 STK
    Briefkurs 17.05.24
    ISIN: US45719W2052 · WKN: A3EMJR · SYM: IKT · USA

    Neueste Nachrichten

    Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity
    16.05.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement
    15.05.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension
    09.05.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
    18.04.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
    03.04.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
    27.03.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
    07.03.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
    28.02.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
    07.02.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
    29.01.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
    16.01.24 · globenewswire · Inhibikase Therapeutics
    Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
    19.12.23 · globenewswire · Inhibikase Therapeutics